Who are Actitan F's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Period B, Ramelteon and zolpidem, Risperidone and Ramelteon, Rozerem, melatonin in children premedication, Sublingual Melatonin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/actitan-f.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Actitan F — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Actitan F (Actitan F) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: melatonin receptor agonist. Area: Sleep disorder.

marketed melatonin receptor agonist MT1/MT2 Sleep disorder Small molecule Live · refreshed every 30 min

Target snapshot

Actitan F (Actitan F) — Federico II University. Actitan F is a melatonin receptor agonist.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Actitan F TARGET	Actitan F	Federico II University	marketed	melatonin receptor agonist	MT1/MT2
Period B	Period B	Apnimed	marketed	melatonin receptor agonist	MT1/MT2 melatonin receptor
Ramelteon and zolpidem	Ramelteon and zolpidem	Takeda	marketed	Hypnotic combination agent	Melatonin receptors (MT1/MT2) and GABA-A receptors
Risperidone and Ramelteon	Risperidone and Ramelteon	All India Institute of Medical Sciences, Bhubaneswar	marketed	Atypical antipsychotic + melatonin receptor agonist combination	Dopamine D2 receptor, serotonin 5-HT2A receptor, melatonin MT1/MT2 receptors
Rozerem	RAMELTEON	Takeda	marketed	Melatonin Receptor Agonist [EPC]	Melatonin receptor type 1A	2005-01-01
melatonin in children premedication	melatonin in children premedication	Azienda Ospedaliera Universitaria Policlinico "G. Martino"	marketed	Melatonin receptor agonist	MT1 and MT2 melatonin receptors
Sublingual Melatonin	Sublingual Melatonin	Al-Azhar University	marketed	Melatonin receptor agonist	MT1 and MT2 melatonin receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (melatonin receptor agonist class)

Apnimed · 1 drug in this class
Federico II University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Actitan F — Competitive Intelligence Brief. https://druglandscape.com/ci/actitan-f. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing